The Prevalence of Human Papilloma Virus Infection Among Women who Admitted to Cukurova University Faculty of Medicine Hospital


Creative Commons License

Altun Z., YARKIN F. , VARDAR M. A. , UĞUZ A. H.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.31, ss.307-314, 2011 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 31 Konu: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.5336/medsci.2009-16463
  • Dergi Adı: TURKIYE KLINIKLERI TIP BILIMLERI DERGISI
  • Sayfa Sayısı: ss.307-314

Özet

Objective: Human papilloma virus (HPV) is the major etiologic agent for cervical cancer. Cervical cancer is the second most prevalent cancer among women in the world. In this study, we aimed to investigate the prevalence of HPV infection among women admitted to Hospital of cukurova University Faculty of Medicine. Material and Methods: A total number of 460 cervical smears were obtained from women aged between 20-68 years. Consensus polymerase chain reaction (PCR) assay using MY09/11 and GP5 + /6 + primers were used to detect HPV DNA. HPV DNA positive samples were further stratified as high risk (HR) and low risk (LR) by using HPVpU-1M/pU-2R and HPVpU-31B/pU-2R primers, respectively. HPV DNA positive samples were also genotyped for HPV 16, 18,31 and 45, which are the most frequently detected genotypes in cervical cancer, by using type-specific PCR. Results: Twenty-four of 460 samples (5.2%) were positive for HPV DNA. Among the 24 HPV DNA positive women, 14 (3%) had single or multiple infection with HR HPV types, 10 (2.2%) had isolated LR HPV positivity. Among 24 women with HPV DNA positivity and aged >= 30 years, the most common HPV genotype was HPV 16 (33.3%), followed by HPV 45 (20.8%), HPV 18 and HPV 31(4.2%), in rank order. Conclusion: The prevalence of genital HPV infection among women who admitted to Hospital of cukurova University Faculty of Medicine was found as 5.2%. Epidemiological studies for HPV infection should be conducted to establish screening strategies for cervical cancer and to demonstrate the feasibility of HPV vaccination.